For real-world visual datasets (like facial dataset or ImageNet), the unavailability of strict counterfactual data is a common challenge.

Such error correlations not only affect the model's ability to make robust predictions but also

Multi-task learning can suffer from destructive task interference, where jointly trained models underperform single-task baselines and limit generalization. To improve generalization performance in breast ultrasound-based tumor segmentation via multi-task learning, we propose a novel consistency regularization approach that mitigates destructive interference between segmentation and classification. The consistency regularization approach is composed of differentiable BI-RADS-inspired morphological features. We validated this approach by training all models on the BrEaST dataset (Poland) and evaluating them on three external datasets: UDIAT (Spain), BUSI (Egypt), and BUS-UCLM (Spain). Our comprehensive analysis demonstrates statistically significant (p<0.001) improvements in generalization for segmentation task of the proposed multi-task approach vs. the baseline one: UDIAT, BUSI, BUS-UCLM (Dice coefficient=0.81 vs 0.59, 0.66 vs 0.56, 0.69 vs 0.49, resp.). The proposed approach also achieves state-of-the-art segmentation performance under rigorous external validation on the UDIAT dataset.

Machine learning models have utilized semantic features, deep features, or both to assess lung nodule malignancy. However, their reliance on manual annotation during inference, limited interpretability, and sensitivity to imaging variations hinder their application in real-world clinical settings. Thus, this research aims to integrate semantic features derived from radiologists' assessments of nodules, guiding the model to learn clinically relevant, robust, and explainable imaging features for predicting lung cancer. We obtained 938 low-dose CT scans from the National Lung Screening Trial (NLST) with 1,261 nodules and semantic features. Additionally, the Lung Image Database Consortium dataset contains 1,018 CT scans, with 2,625 lesions annotated for nodule characteristics. Three external datasets were obtained from UCLA Health, the LUNGx Challenge, and the Duke Lung Cancer Screening. We fine-tuned a pretrained Contrastive Language-Image Pretraining (CLIP) model with a parameter-efficient fine-tuning approach to align imaging and semantic text features and predict the one-year lung cancer diagnosis. Our model outperformed state-of-the-art (SOTA) models in the NLST test set with an AUROC of 0.901 and AUPRC of 0.776. It also showed robust results in external datasets. Using CLIP, we also obtained predictions on semantic features through zero-shot inference, such as nodule margin (AUROC: 0.807), nodule consistency (0.812), and pleural attachment (0.840). Our approach surpasses the SOTA models in predicting lung cancer across datasets collected from diverse clinical settings, providing explainable outputs, aiding clinicians in comprehending the underlying meaning of model predictions. This approach also prevents the model from learning shortcuts and generalizes across clinical settings. The code is available at https://github.com/luotingzhuang/CLIP_nodule.

Such error correlations not only affect the model's ability to make robust predictions but also

Recent studies have shown that Machine Learning (ML) models can exhibit bias in real-world scenarios, posing significant challenges in ethically sensitive domains such as healthcare. Such bias can negatively affect model fairness, model generalization abilities and further risks amplifying social discrimination. There is a need to remove biases from trained models. Existing debiasing approaches often necessitate access to original training data and need extensive model retraining; they also typically exhibit trade-offs between model fairness and discriminative performance. To address these challenges, we propose Soft-Mask Weight Fine-Tuning (SWiFT), a debiasing framework that efficiently improves fairness while preserving discriminative performance with much less debiasing costs. Notably, SWiFT requires only a small external dataset and only a few epochs of model fine-tuning. The idea behind SWiFT is to first find the relative, and yet distinct, contributions of model parameters to both bias and predictive performance. Then, a two-step fine-tuning process updates each parameter with different gradient flows defined by its contribution. Extensive experiments with three bias sensitive attributes (gender, skin tone, and age) across four dermatological and two chest X-ray datasets demonstrate that SWiFT can consistently reduce model bias while achieving competitive or even superior diagnostic accuracy under common fairness and accuracy metrics, compared to the state-of-the-art. Specifically, we demonstrate improved model generalization ability as evidenced by superior performance on several out-of-distribution (OOD) datasets.

Drug discovery is a complex and resource-intensive process, making early prediction of approval outcomes critical for optimizing research investments. While classical machine learning and deep learning methods have shown promise in drug approval prediction, their limited interpretability constraints their impact. Here, we present DrugReasoner, a reasoning-based large language model (LLM) built on the LLaMA architecture and fine-tuned with group relative policy optimization (GRPO) to predict the likelihood of small-molecule approval. DrugReasoner integrates molecular descriptors with comparative reasoning against structurally similar approved and unapproved compounds, generating predictions alongside step-by-step rationales and confidence scores. DrugReasoner achieved robust performance with an AUC of 0.732 and an F1 score of 0.729 on the validation set and 0.725 and 0.718 on the test set, respectively. These results outperformed conventional baselines, including logistic regression, support vector machine, and k-nearest neighbors and had competitive performance relative to XGBoost. On an external independent dataset, DrugReasoner outperformed both baseline and the recently developed ChemAP model, achieving an AUC of 0.728 and an F1-score of 0.774, while maintaining high precision and balanced sensitivity, demonstrating robustness in real-world scenarios. These findings demonstrate that DrugReasoner not only delivers competitive predictive accuracy but also enhances transparency through its reasoning outputs, thereby addressing a key bottleneck in AI-assisted drug discovery. This study highlights the potential of reasoning-augmented LLMs as interpretable and effective tools for pharmaceutical decision-making.

The development of multi-label deep learning models for retinal disease classification is often hindered by the scarcity of large, expertly annotated clinical datasets due to patient privacy concerns and high costs. The recent release of SynFundus-1M, a high-fidelity synthetic dataset with over one million fundus images, presents a novel opportunity to overcome these barriers. To establish a foundational performance benchmark for this new resource, we developed an end-to-end deep learning pipeline, training six modern architectures (ConvNeXtV2, SwinV2, ViT, ResNet, EfficientNetV2, and the RETFound foundation model) to classify eleven retinal diseases using a 5-fold multi-label stratified cross-validation strategy. We further developed a meta-ensemble model by stacking the out-of-fold predictions with an XGBoost classifier. Our final ensemble model achieved the highest performance on the internal validation set, with a macro-average Area Under the Receiver Operating Characteristic Curve (AUC) of 0.9973. Critically, the models demonstrated strong generalization to three diverse, real-world clinical datasets, achieving an AUC of 0.7972 on a combined DR dataset, an AUC of 0.9126 on the AIROGS glaucoma dataset and a macro-AUC of 0.8800 on the multi-label RFMiD dataset. This work provides a robust baseline for future research on large-scale synthetic datasets and establishes that models trained exclusively on synthetic data can accurately classify multiple pathologies and generalize effectively to real clinical images, offering a viable pathway to accelerate the development of comprehensive AI systems in ophthalmology.